Humacyte (HUMA) Total Current Liabilities (2020 - 2026)
Humacyte (HUMA) posted quarterly Total Current Liabilities of $16.2 million for Q1 2026, down 19.18% year-over-year from $20.0 million in Q1 2025, and down 11.89% quarter-over-quarter from $18.4 million in Q4 2025.
Humacyte (HUMA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Total Current Liabilities for 7 consecutive years, with $16.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 19.18% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at $16.2 million (down 19.18% YoY), while the FY2025 annual figure was $18.4 million, down 7.93% from the prior year.
- Total Current Liabilities slipped to $16.2 million in Q1 2026 per HUMA's latest filing, from $18.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $25.6 million in Q3 2025 and bottomed at $10.8 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $17.8 million across 5 years, with a median of $18.4 million in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 7834.57% — and 2024, when it tumbled 40.31%.
- Humacyte's Total Current Liabilities stood at $19.6 million in 2022, then dropped by 5.81% to $18.4 million in 2023, then grew by 8.19% to $20.0 million in 2024, then retreated by 7.93% to $18.4 million in 2025, then decreased by 11.89% to $16.2 million in 2026.
- Business Quant data shows HUMA's Total Current Liabilities at $16.2 million in Q1 2026, $18.4 million in Q4 2025, and $25.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 630.93 Mn |
| 10 | Humacyte | 154.19 Mn | 154.19 Mn | -825,000.00 | 14.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.95 Mn |
| Mar 31, 2026 | 16.19 Mn |
| Dec 31, 2025 | 18.37 Mn |
| Sep 30, 2025 | 25.58 Mn |
| Jun 30, 2025 | 21.09 Mn |
| Mar 31, 2025 | 20.03 Mn |
| Dec 31, 2024 | 19.95 Mn |
| Sep 30, 2024 | 20.94 Mn |
| Jun 30, 2024 | 17.76 Mn |
| Mar 31, 2024 | 14.09 Mn |
| Dec 31, 2023 | 18.44 Mn |
| Sep 30, 2023 | 15.14 Mn |
| Jun 30, 2023 | 11.39 Mn |
| Mar 31, 2023 | 23.60 Mn |
| Dec 31, 2022 | 19.58 Mn |
| Sep 30, 2022 | 17.91 Mn |
| Jun 30, 2022 | 11.06 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | 11.05 Mn |
| Sep 30, 2021 | 21.25 Mn |